Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MesoblastSTU:LWB -2.01%56 FCF Margin % is -43.40% as of Jun. 2026. GuruFocus rates STU:LWB with a GF Score™ of 56/100. The stock has 2 warning signs investors should review. Among 976 Biotechnology companies, Mesoblast ranks better than 53.48% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mesoblast's Free Cash Flow for the
six
months ended in Jun. 2026 was €-25.6 Mil. Mesoblast's Revenue for the
six
months ended in Jun. 2026 was €59.1 Mil. Therefore, Mesoblast's FCF Margin % for the quarter that ended in Jun. 2026 was -43.40%.
The historical data trend for Mesoblast's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LWB vs VRTX, REGN, MRNA: FCF Margin % Comparison
For the Biotechnology subindustry, Mesoblast's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mesoblast's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesoblast (STU:LWB) has a FCF Margin % of -43.40% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mesoblast and its competitors. According to the industry distribution chart, Mesoblast ranks #454 out of 976 companies in the Biotechnology industry, placing it in the top 46.5%.
Is Mesoblast's FCF Margin % too high?
Mesoblast's current FCF Margin % is -43.40%. Based on the distribution chart, Mesoblast ranks #454 out of 976 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mesoblast has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #454 out of 976 companies for FCF Margin %. This puts Mesoblast in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mesoblast and its competitors. Mesoblast's current FCF Margin % is -43.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (STU:LWB) has a current FCF Margin % of -43.40%. The current FCF Margin % is -43.40%. Mesoblast's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mesoblast (STU:LWB), the current FCF Margin % is -43.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
56GF Score
Get the complete analysis for STU:LWB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LWB has been successfully added to your 
